Conversion from cyclosporine to tacrolimus in patients at risk for chronic renal allograft failure

60-Month results of the CRAF study

Fuad S. Shihab, Thomas H. Waid, David J. Conti, Harold Yang, Michael J. Holman, Laura L Mulloy, Alice K. Henning, John Holman, M. Roy First

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

BACKGROUND. This study compared the long-term effects of switching from cyclosporine to tacrolimus on the incidence, progression, and severity of chronic renal allograft failure in patients with elevated serum creatinine levels. METHODS. Patients were assigned randomly (2:1) to switch to tacrolimus or remain on cyclosporine. Tacrolimus was initiated at 1/50th of the cyclosporine dose or 0.15 mg/kg/day, whichever dose was lower, to maintain trough concentrations between 5 and 15 ng/mL. Cyclosporine doses were adjusted to achieve trough concentrations between 100 and 300 ng/mL. RESULTS. At 60 months, the median change from baseline in serum creatinine was -0.2 mg/dL in the tacrolimus group and 0.3 mg/dL in the cyclosporine group (P=0.003). Median change in estimated creatinine clearance was 1.2 mL/min in the tacrolimus group and -4.1 mL/min in the cyclosporine group (P=0.019). The incidence of new-onset diabetes, hyperglycemia, hypertension, lymphoma, and malignancies was generally low and comparable between groups. Fewer patients in the tacrolimus group than in the cyclosporine group developed new cardiac conditions (11% vs. 28%, P=0.004), had low-density lipoprotein (LDL) cholesterol values more than 130 mg/dL (29% vs. 57%, P=0.002), or developed hyperlipidemia (24% vs. 67%, P=0.046) during the 60-month follow-up period. Despite these changes, patient and graft survival were similar for both groups. CONCLUSION. Switching from cyclosporine to tacrolimus resulted in improved renal function and a reduction in the occurrence of new-onset cardiac conditions and hyperlipidemia, with no increase in the incidence of new-onset diabetes or new-onset hyperglycemia. However, after 5 years there was no impact on patient or graft survival.

Original languageEnglish (US)
Pages (from-to)1261-1269
Number of pages9
JournalTransplantation
Volume85
Issue number9
DOIs
StatePublished - May 1 2008

Fingerprint

Tacrolimus
Cyclosporine
Chronic Kidney Failure
Allografts
Creatinine
Graft Survival
Hyperlipidemias
Hyperglycemia
Incidence
Serum
LDL Cholesterol
Lymphoma
Hypertension
Kidney

Keywords

  • Cyclosporine
  • Graft rejection
  • Renal transplantation
  • Tacrolimus

ASJC Scopus subject areas

  • Transplantation

Cite this

Conversion from cyclosporine to tacrolimus in patients at risk for chronic renal allograft failure : 60-Month results of the CRAF study. / Shihab, Fuad S.; Waid, Thomas H.; Conti, David J.; Yang, Harold; Holman, Michael J.; Mulloy, Laura L; Henning, Alice K.; Holman, John; First, M. Roy.

In: Transplantation, Vol. 85, No. 9, 01.05.2008, p. 1261-1269.

Research output: Contribution to journalArticle

Shihab, Fuad S. ; Waid, Thomas H. ; Conti, David J. ; Yang, Harold ; Holman, Michael J. ; Mulloy, Laura L ; Henning, Alice K. ; Holman, John ; First, M. Roy. / Conversion from cyclosporine to tacrolimus in patients at risk for chronic renal allograft failure : 60-Month results of the CRAF study. In: Transplantation. 2008 ; Vol. 85, No. 9. pp. 1261-1269.
@article{af407e72dbd44c36a88c5688e8db5622,
title = "Conversion from cyclosporine to tacrolimus in patients at risk for chronic renal allograft failure: 60-Month results of the CRAF study",
abstract = "BACKGROUND. This study compared the long-term effects of switching from cyclosporine to tacrolimus on the incidence, progression, and severity of chronic renal allograft failure in patients with elevated serum creatinine levels. METHODS. Patients were assigned randomly (2:1) to switch to tacrolimus or remain on cyclosporine. Tacrolimus was initiated at 1/50th of the cyclosporine dose or 0.15 mg/kg/day, whichever dose was lower, to maintain trough concentrations between 5 and 15 ng/mL. Cyclosporine doses were adjusted to achieve trough concentrations between 100 and 300 ng/mL. RESULTS. At 60 months, the median change from baseline in serum creatinine was -0.2 mg/dL in the tacrolimus group and 0.3 mg/dL in the cyclosporine group (P=0.003). Median change in estimated creatinine clearance was 1.2 mL/min in the tacrolimus group and -4.1 mL/min in the cyclosporine group (P=0.019). The incidence of new-onset diabetes, hyperglycemia, hypertension, lymphoma, and malignancies was generally low and comparable between groups. Fewer patients in the tacrolimus group than in the cyclosporine group developed new cardiac conditions (11{\%} vs. 28{\%}, P=0.004), had low-density lipoprotein (LDL) cholesterol values more than 130 mg/dL (29{\%} vs. 57{\%}, P=0.002), or developed hyperlipidemia (24{\%} vs. 67{\%}, P=0.046) during the 60-month follow-up period. Despite these changes, patient and graft survival were similar for both groups. CONCLUSION. Switching from cyclosporine to tacrolimus resulted in improved renal function and a reduction in the occurrence of new-onset cardiac conditions and hyperlipidemia, with no increase in the incidence of new-onset diabetes or new-onset hyperglycemia. However, after 5 years there was no impact on patient or graft survival.",
keywords = "Cyclosporine, Graft rejection, Renal transplantation, Tacrolimus",
author = "Shihab, {Fuad S.} and Waid, {Thomas H.} and Conti, {David J.} and Harold Yang and Holman, {Michael J.} and Mulloy, {Laura L} and Henning, {Alice K.} and John Holman and First, {M. Roy}",
year = "2008",
month = "5",
day = "1",
doi = "10.1097/TP.0b013e31816b4388",
language = "English (US)",
volume = "85",
pages = "1261--1269",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "9",

}

TY - JOUR

T1 - Conversion from cyclosporine to tacrolimus in patients at risk for chronic renal allograft failure

T2 - 60-Month results of the CRAF study

AU - Shihab, Fuad S.

AU - Waid, Thomas H.

AU - Conti, David J.

AU - Yang, Harold

AU - Holman, Michael J.

AU - Mulloy, Laura L

AU - Henning, Alice K.

AU - Holman, John

AU - First, M. Roy

PY - 2008/5/1

Y1 - 2008/5/1

N2 - BACKGROUND. This study compared the long-term effects of switching from cyclosporine to tacrolimus on the incidence, progression, and severity of chronic renal allograft failure in patients with elevated serum creatinine levels. METHODS. Patients were assigned randomly (2:1) to switch to tacrolimus or remain on cyclosporine. Tacrolimus was initiated at 1/50th of the cyclosporine dose or 0.15 mg/kg/day, whichever dose was lower, to maintain trough concentrations between 5 and 15 ng/mL. Cyclosporine doses were adjusted to achieve trough concentrations between 100 and 300 ng/mL. RESULTS. At 60 months, the median change from baseline in serum creatinine was -0.2 mg/dL in the tacrolimus group and 0.3 mg/dL in the cyclosporine group (P=0.003). Median change in estimated creatinine clearance was 1.2 mL/min in the tacrolimus group and -4.1 mL/min in the cyclosporine group (P=0.019). The incidence of new-onset diabetes, hyperglycemia, hypertension, lymphoma, and malignancies was generally low and comparable between groups. Fewer patients in the tacrolimus group than in the cyclosporine group developed new cardiac conditions (11% vs. 28%, P=0.004), had low-density lipoprotein (LDL) cholesterol values more than 130 mg/dL (29% vs. 57%, P=0.002), or developed hyperlipidemia (24% vs. 67%, P=0.046) during the 60-month follow-up period. Despite these changes, patient and graft survival were similar for both groups. CONCLUSION. Switching from cyclosporine to tacrolimus resulted in improved renal function and a reduction in the occurrence of new-onset cardiac conditions and hyperlipidemia, with no increase in the incidence of new-onset diabetes or new-onset hyperglycemia. However, after 5 years there was no impact on patient or graft survival.

AB - BACKGROUND. This study compared the long-term effects of switching from cyclosporine to tacrolimus on the incidence, progression, and severity of chronic renal allograft failure in patients with elevated serum creatinine levels. METHODS. Patients were assigned randomly (2:1) to switch to tacrolimus or remain on cyclosporine. Tacrolimus was initiated at 1/50th of the cyclosporine dose or 0.15 mg/kg/day, whichever dose was lower, to maintain trough concentrations between 5 and 15 ng/mL. Cyclosporine doses were adjusted to achieve trough concentrations between 100 and 300 ng/mL. RESULTS. At 60 months, the median change from baseline in serum creatinine was -0.2 mg/dL in the tacrolimus group and 0.3 mg/dL in the cyclosporine group (P=0.003). Median change in estimated creatinine clearance was 1.2 mL/min in the tacrolimus group and -4.1 mL/min in the cyclosporine group (P=0.019). The incidence of new-onset diabetes, hyperglycemia, hypertension, lymphoma, and malignancies was generally low and comparable between groups. Fewer patients in the tacrolimus group than in the cyclosporine group developed new cardiac conditions (11% vs. 28%, P=0.004), had low-density lipoprotein (LDL) cholesterol values more than 130 mg/dL (29% vs. 57%, P=0.002), or developed hyperlipidemia (24% vs. 67%, P=0.046) during the 60-month follow-up period. Despite these changes, patient and graft survival were similar for both groups. CONCLUSION. Switching from cyclosporine to tacrolimus resulted in improved renal function and a reduction in the occurrence of new-onset cardiac conditions and hyperlipidemia, with no increase in the incidence of new-onset diabetes or new-onset hyperglycemia. However, after 5 years there was no impact on patient or graft survival.

KW - Cyclosporine

KW - Graft rejection

KW - Renal transplantation

KW - Tacrolimus

UR - http://www.scopus.com/inward/record.url?scp=43449132120&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=43449132120&partnerID=8YFLogxK

U2 - 10.1097/TP.0b013e31816b4388

DO - 10.1097/TP.0b013e31816b4388

M3 - Article

VL - 85

SP - 1261

EP - 1269

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 9

ER -